학술논문
60MO Real-world overall and progression-free survival for first-line immunotherapy-based regimens in advanced non-small cell lung cancer
Document Type
Abstract
Author
Source
In Immuno-Oncology and Technology December 2022 16 Supplement 1
Subject
Language
ISSN
2590-0188